Oncology News

The addition of zolbetuximab to chemotherapy improved PFS among certain patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

Perioperative complication rates were similar between simultaneous and delayed resection of liver metastasis and colorectal cancer, although survival benefits of simultaneous resection were greater in patients with KRAS wild-type tumors.

The Liver Meeting 2022 delivered the latest research and developments on a variety of topics, including acute hepatitis in children, treatment for hepatitis-related cirrhosis and liver disease mortality during the COVID-19 pandemic.

In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses challenges in diagnosing cholangiocarcinoma during the COVID-19 pandemic.

In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses the current landscape of targeted treatment in cholangiocarcinoma.

In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses understanding the tumor landscape of cholangiocarcinoma.

In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses areas of unmet need, including early diagnosis.

CHARLOTTE, N.C. — Pancreatic cancer screenings in high-risk individuals identified high-risk lesions in nearly 1% of patients and intermediate-risk pathology in more than 30%, according to data presented at the ACG Annual Scientific Meeting.

The addition of pembrolizumab to chemotherapy improved OS among certain patients with gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

The FDA granted orphan drug designation to ZB131 for treatment of cholangiocarcinoma, according to the agent’s manufacturer.